LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Karner, C; Cates, CJ (2011)
Publisher: WILEY-BLACKWELL
Languages: English
Types: Article
Subjects: Article
BackgroundLong-acting bronchodilators comprising long-acting beta(2)-agonists and the anticholinergic agent tiotropiumare commonly used, either on their own or in combination, for managing persistent symptoms of chronic obstructive pulmonary disease. Patients with severe chronic obstructive pulmonary disease who are symptomatic and who suffer repeated exacerbations are recommended to add inhaled corticosteroids to their bronchodilator treatment. However, the benefits and risks of adding inhaled corticosteroid to tiotropium and long-acting beta2-agonists for the treatment of chronic obstructive pulmonary disease are unclear.ObjectivesTo assess the relative effects of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists treatment in patients with chronic obstructive pulmonary disease.Search strategyWe searched the Cochrane Airways Group Specialised Register of trials (February 2011) and reference lists of articles.Selection criteriaWe included parallel group, randomised controlled trials of three months or longer comparing inhaled corticosteroid and long-acting beta(2)-agonist combination therapy in addition to inhaled tiotropium against tiotropium and long-acting beta2-agonist treatment for patients with chronic obstructive pulmonary disease (COPD).Data collection and analysisTwo review authors independently assessed trials for inclusion and then extracted data on trial quality and the outcome results. We contacted study authors for additional information. We collected information on adverse effects from the trials.Main resultsOne trial (293 patients) was identified comparing tiotropium in addition to inhaled corticosteroid and long-acting beta(2)-agonist combination therapy to tiotropium plus long-acting beta2-agonist. The study was of good methodological quality, however it suffered from high and uneven withdrawal rates between the treatment arms. There is currently insufficient evidence to know how much difference the addition of inhaled corticosteroids makes to people who are taking tiotropium and a long-acting beta(2)-agonist for COPD.Authors' conclusionsThe relative efficacy and safety of adding inhaled corticosteroid to tiotropium and a long-acting beta(2)-agonist for chronic obstructive pulmonary disease patients remains uncertain and additional trials are required to answer this question.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Aaron 2007 {published data only} Aaron SD, Vandemheen K, Ferguson D, FitzGerald M, Maltais F, Boureau J, et al.The Canadian optimal therapy of COPD trial: Design, organization and patient recruitment. Canadian Respiratory Journal 2004;11(8):581-5. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al.Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. [see comment] [summary for patients in Annals of Internal Medicine 2007 Apr 17;146(8):I12; PMID: 17310044]. Annals of Internal Medicine 2007;146 (8):545-55.
    • Kaplan A. Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal 2007;16(4): 258-60.
    • Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, et al.Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008; 63(11):962-7.
    • Roisman G. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique 2007;63(6):390-1.
    • Golabi 2006 {published data only} Golabi P, Topaloglu N, Karakurt S, Celikel T. Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation dyspnea and exercise tolerance in COPD [Abstract]. European Respiratory Journal. 2006; Vol. 28, issue Suppl 50:33s [E304].
    • Hara 2007 {published data only} Hara K, Kurashima K, Tokunaga D, Ueno M, Aoyagi K, Isobe Z, et al.Single blind comparison of tiotropium and salmeterol plus fluticasone propionate of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference, May 18-23, 2007, San Francisco, California, USA. 2007:Poster #A1.
    • Mittmann 2010 {published data only} Mittmann N, Hernandez P, Mellström C, Brannman L, Welte T. Cost-effectiveness of budesonide/formoterol added to tiotropium in COPD patients in Canada, Australia and Sweden [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22. 2010: [5183].
    • Singh 2008 {published data only} Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63 (7):592-8.
    • American Thoracic Society International Conference, May 16-21, 2008, Toronto. 2008:A648[#F10].
    • Agarwal 2010 Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing COPD exacerbations. Chest 2010;137(2):318-25.
    • Akazawa 2008 Akazawa M, Hayflinger DC, Stanford RH, Blanchette CM. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. The American Journal of Managed Care 2008;14(7):438-48.
    • Appleton 2006 Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MMK, et al.Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/ 14651858.CD001104.pub2]
    • Barr 2005 Barr RG, Bourbeau J, Camargo Carlos A. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2]
    • Beeh 2010 Beeh KM, Beier J. The short, the long, and the “ultra-long”: Why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Advances in Therapy 2010; 27(3):150-9.
    • Berger 2008 Berger WE, Nadel JA. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respiratory Medicine 2008;102(2):173-88.
    • Briggs 2010 Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PMA, Jones PW, et al.Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal 2010;35(3):532-9.
    • Calverley 2007 Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al.TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. The New England Journal of Medicine 2007;356(8):775-89.
    • Dalal 2010 Dalal AA, St Charles M, Petersen HV, Roberts MH, Blanchette CM, Manavi-Zieverink K. Cost-effectiveness van der Meer 2001 van der Meer RM, Wagena E, Ostelo RWJG, Jacobs AJE, van Schayck O. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD002999] Wallukat 2002 Wallukat G. The beta-adrenergic receptors. Herz 2002;27 (7):683-90.
    • Welsh 2010 Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/ 14651858.CD007891] World Health Organization. Chronic Respiratory Diseases. www.who.int.
    • Yang 2007 Yang IA, Fong K, Sim EHA, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD002991.pub2] ∗ Indicates the major publication for the study O F C O N T R I B U T I O N S A U T H O R S
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article